mRFP-mem
(Plasmid
#55622)
-
PurposeThis red fluorescent plasma membrane marker consists of the first twenty residues of neuromodulin fused to mRFP.
-
Depositing Lab
-
Depositing OrganizationGeisinger Health Center
Located in the United States of America -
Sequence Information
Ordering
| Item | Catalog # | Description | Quantity | Price (USD) | |
|---|---|---|---|---|---|
| Plasmid | 55622 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $94 | |
| DNA | 55622-D50 | 50 μg of DNA in Tris buffer | $495 | ||
| DNA | 55622-D100 | 100 μg of DNA in Tris buffer | $585 | ||
Backbone
-
Vector backboneDerived from pEYFP-Mem
-
Backbone manufacturerClontech
- Backbone size w/o insert (bp) 3942
- Total vector size (bp) 4750
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH10B
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namemRFP-Mem
-
SpeciesDiscosoma sp.
-
Insert Size (bp)808
- Promoter CMV
-
Tag
/ Fusion Protein
- The N-terminal 20 residues of neuromodulin are fused to the N-terminus of mRFP.
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site BglII (not destroyed)
- 3′ cloning site NotI (not destroyed)
- 5′ sequencing primer CMV Forward
- 3′ sequencing primer sV40pA-Reverse
- (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made bymRFP1/pcDNA3 was obtained from Roger Tsien, University of California, San Diego. pEYFP-Mem was purchased from Clontech.
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Reference for mRFP:
Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA, et al. A monomeric red fluorescent protein. Proc Natl Acad Sci U S A. 2002;99(12):7877-82. PubMed PMID: 12060735.
DNA (Catalog # 55622-D50)
Purpose
Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.
Delivery
- Amount 50 μg
- Concentration 1 μg/μL
- Pricing $495 USD
- Storage 4 ℃ (short-term) or -20 ℃ (long-term)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Quality Control
Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.
Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.
DNA (Catalog # 55622-D100)
Purpose
Ready-to-use, high-purity DNA prep. DNA aliquots are suitable for use in mammalian cell transfections and other molecular biology applications.
Delivery
- Amount 100 μg
- Concentration 1 μg/μL
- Pricing $585 USD
- Storage 4 ℃ (short-term) or -20 ℃ (long-term)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Quality Control
Every DNA prep is verified by next-generation sequencing, confirming plasmid identity, sequence integrity, and absence of DNA contaminants. Concentration is confirmed to be within ±2.5% of the stated concentration.
Our production process has been validated to consistently yield endotoxin levels below 1.0 EU/μg. Individual lots are not tested for endotoxin.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
mRFP-mem was a gift from Catherine Berlot (Addgene plasmid # 55622 ; http://n2t.net/addgene:55622 ; RRID:Addgene_55622) -
For your References section:
Analysis of G protein betagamma dimer formation in live cells using multicolor bimolecular fluorescence complementation demonstrates preferences of beta1 for particular gamma subunits. Mervine SM, Yost EA, Sabo JL, Hynes TR, Berlot CH. Mol Pharmacol. 2006 Jul;70(1):194-205. Epub 2006 Apr 26. 10.1124/mol.106.022616 PubMed 16641313